

Basingstoke, Southampton and Winchester

District Prescribing Committee (DPC)

Recommendations of the meeting of 9th December 2014

Supported or limited support e.g. Specialist recommendation

- **Flivasorb® absorbent dressing-** The Wound Formulary subgroup have recommended this to replace Drymax Extra® on the local formulary. The DPC supported the recommendation that Flivasorb® should now be the 'super absorber' of choice locally, based on greatest absorbency, performance when full, conformability and cost effectiveness.
- **Clinipod®-** The DPC supported the recommendation that Clinipod should now be the local formulary product of choice, replacing Irripod®, due to superior cost-effectiveness.
- **Agreed list of dermatology 'specials' for local use-** The DPC agreed a list of around 25 preparations that are supported for local use, including an indication of their suggested red/amber/green status for prescribing.

Not supported currently

- **Insulin degludec and liraglutide (IDegLira) combination (Xultophy®)-** This product is not supported for local use currently, pending a review by the DPC diabetes subgroup. Insulin degludec is currently positioned locally for use in patients with 'brittle' type 1 diabetes, following specialist recommendation, prior to considering insulin pump therapy. Liraglutide is used as a second or third line option in type 2 diabetes currently.
- **Vedolizumab for use in Ulcerative Colitis or Crohn's Disease-** This was not supported for routine use currently, pending NICE guidance, expected spring 2015. Exceptional use via the IFR (Individual Funding Request) route is suggested in the meantime.
- **GutLife and EvaLife creams-** These creams can be used to protect skin in patients undergoing radiotherapy to the genital area. They are not licensed as medicines nor are they currently prescribable on FP10. The DPC did not support NHS prescribing, although noted that they can be purchased.

Other Information/ Reminders

- **Type 2 Diabetes Stepped Approach Guidance -** Updated and supported for local use. The guidance is now available via the West Hampshire CCG website (no password required) http://www.westhampshireccg.nhs.uk/documents/cat_view/84-medicines/92-guidance- In addition UHS will be carrying out a review of their diabetes formulary in early 2015.
- **Shared Care Guidelines (SCG) approved locally-** SCGs for lubiprostone and prucalopride in chronic constipation are now available on the WHCCG website : http://www.westhampshireccg.nhs.uk/documents/cat_view/84-medicines/87-shared-care-guidelines

Summarised on behalf of the District Prescribing Committee

Julia Bowey (Southampton City CCG) 17.12.14